FP agonists, including latanoprost, inhibit adipogenesis by stimulating FP receptor in 3T3-L1 cells.21 Prostaglandin F2α (PGF2α) also inhibits adipocyte differentiation by binding the FP receptor.22 Hence, DUES due to current anti-glaucoma FP agonists likely follows inhibition of adipogenesis around the eyelid, followed by atrophy of orbital fat. Here, PTGFR is linked to glaucoma.